论文部分内容阅读
目的探讨雌激素受体α(ERα)、雌激素受体β(ERβ)、孕激素受体(PR)、人类表皮生长因子受体2(HER2)在乳腺癌组织中的表达及其与TNM分期和腋窝淋巴结状况的关系。方法随机选择我院在2004年12月至2007年12月收治的HER2高表达(+++)51例与无表达(-)53例乳腺浸润性导管癌病例,分别检测乳腺癌组织的ERα、ERβ、PR的表达水平,分析其与TNM分期、腋窝淋巴结转移等临床指标的相关性。结果104例乳腺癌患者,TNM分期为I期的占14.42%,Ⅱ期占62.50%,Ⅲ期占19.23%,IV期占3.85%;HER2阳性的淋巴结转移率为41.18%,HER2阴性的转移率为47.5%;ERα、ERβ、PR的阳性表达率分别为52.88%、63.46%、73.08%。ERβ与ERα、PR的表达呈正相关(P<0.01),与HER2的表达负相关(P<0.01);ERα与PR的表达正相关(P<0.01),与HER2负相关(P<0.01),PR与HER2的表达负相关(P<0.05);ERα、ERβ、PR、HER2的表达与淋巴结转移情况及TNM分期无显著相关性。结论HER2作为乳腺癌预后不良的重要指标与作为乳腺癌预后良好的重要指标ERα、ERβ、PR的表达呈负相关,与TNM分期及腋窝淋巴结转移状态未显示明显相关性。
Objective To investigate the expression of estrogen receptor α (ERα), estrogen receptor β (ERβ), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in breast cancer and its relationship with TNM stage And axillary lymph node status. Methods 51 cases of HER2 overexpression (+++) and 53 cases of non-expressing (-) invasive ductal carcinoma of the breast were enrolled from December 2004 to December 2007 in our hospital. ERα, ERβ, PR expression levels, and TNM staging, axillary lymph node metastasis and other clinical indicators of relevance. Results In 104 cases of breast cancer, TNM stage I accounted for 14.42%, stage II 62.50%, stage III 19.23%, stage IV 3.85%; HER2 positive lymph node metastasis rate 41.18%, HER2 negative metastasis rate Was 47.5%. The positive expression rates of ERα, ERβ and PR were 52.88%, 63.46% and 73.08% respectively. The expression of ERβ was positively correlated with the expression of ERα and PR (P <0.01), but negatively correlated with the expression of HER2 (P <0.01). The expression of ERα was positively correlated with PR (P <0.01) PR was negatively correlated with the expression of HER2 (P <0.05). The expression of ERα, ERβ, PR and HER2 had no significant correlation with lymph node metastasis and TNM stage. Conclusion HER2 as a negative prognostic factor of breast cancer is negatively correlated with the expression of ERα, ERβ and PR as a good prognostic factor in breast cancer, but not with TNM staging and axillary lymph node metastasis.